Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Use of methotrexate in ANCA-associated vasculitides.

Reinhold-Keller E, de Groot K.

Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S178-82. Epub 2010 Oct 28. Review.

PMID:
21044456
2.

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.

Arthritis Rheum. 2005 Aug;52(8):2461-9.

3.

Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne DR; European Vasculitis Study Group.

Arthritis Rheum. 2012 Oct;64(10):3472-7. doi: 10.1002/art.34547.

4.

Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.

Lally L, Spiera R.

Rheum Dis Clin North Am. 2015;41(1):1-19, vii. doi: 10.1016/j.rdc.2014.09.003. Review.

PMID:
25399936
5.

[Treatment of ANCA-associated vascularitides].

Guillevin L, Pagnoux C.

Presse Med. 2007 May;36(5 Pt 2):922-7. Epub 2007 Apr 3. Review. French.

PMID:
17408912
6.
7.

Rituximab for treatment of severe renal disease in ANCA associated vasculitis.

Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan MD, Cavero T, Eriksson P, Seo P, Manno RL, Dale J, Harper L, Tesar V, Jayne DR.

J Nephrol. 2016 Apr;29(2):195-201. doi: 10.1007/s40620-015-0208-y. Epub 2015 May 19.

PMID:
25986390
8.

L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: different outcomes?

Holle JU.

Presse Med. 2013 Apr;42(4 Pt 2):616-9. doi: 10.1016/j.lpm.2013.01.041. Epub 2013 Mar 6. No abstract available.

PMID:
23481358
9.

ANCA-associated vasculitis: diagnostic and therapeutic strategy.

Ozaki S.

Allergol Int. 2007 Jun;56(2):87-96. Epub 2007 May 1. Review.

10.

Seven clinical conundrums in the treatment of ANCA-associated vasculitis.

Alba MA, Flores-Suárez LF.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S74-83. Epub 2013 Apr 19. Review.

PMID:
23663685
11.

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.

Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104.

12.

[Uptodate in the management and treatment of ANCA-associated vasculitis].

Belaconi IN, Toma CL, Bogdan MA.

Pneumologia. 2014 Apr-Jun;63(2):78-80, 83-6. Review. Romanian.

PMID:
25241554
13.

Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.

Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, Roberson G, Langford CA, Hoffman GS.

Medicine (Baltimore). 2007 Sep;86(5):269-77.

14.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; European Vasculitis Society (EUVAS).

Ann Rheum Dis. 2015 Jun;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404. Epub 2015 Mar 4.

PMID:
25739829
15.
16.

L44. Management of relapses in vasculitis.

Mouthon L.

Presse Med. 2013 Apr;42(4 Pt 2):619-22. doi: 10.1016/j.lpm.2013.02.307. Epub 2013 Mar 7. Review. No abstract available.

PMID:
23477710
17.

Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.

Rich EN, Brown KK.

Curr Opin Pulm Med. 2012 Sep;18(5):447-54. doi: 10.1097/MCP.0b013e32835701d6. Review.

PMID:
22854508
18.

Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring.

Wang T, Weigt SS, Belperio JA, Lynch JP 3rd.

Semin Respir Crit Care Med. 2011 Jun;32(3):346-70. doi: 10.1055/s-0031-1279831. Epub 2011 Jun 14. Review.

PMID:
21674420
19.

Treatment of ANCA-associated vasculitides (AAV).

Holle JU, Gross WL.

Autoimmun Rev. 2013 Feb;12(4):483-6. doi: 10.1016/j.autrev.2012.08.007. Epub 2012 Aug 16. Review.

PMID:
22921792
20.

Clinical features and outcomes of ANCA-associated renal vasculitis.

Seck SM, Dussol B, Brunet P, Burtey S.

Saudi J Kidney Dis Transpl. 2012 Mar;23(2):301-5.

Supplemental Content

Support Center